Strengths and prices
| Strength | Price per vial | Availability | Batch | |
|---|---|---|---|---|
| 5 mg | $40.00 | Low stock | — |
Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.
What it is
SLU-PP-332 is a small molecule, not a peptide. It is an agonist of the estrogen-related receptors (ERR alpha, beta and gamma), which regulate genes of mitochondrial energy metabolism.
Identity
| Type | Small molecule |
|---|---|
| Molecular formula | C18H14N2O2 |
| Molecular weight | 290.3 g/mol |
| CAS number | 303760-60-3 |
| PubChem CID | 5338394 |
SLU-PP-332 is a small molecule, not a peptide: 4-hydroxy-N'-[(E)-naphthalen-2-ylmethylidene]benzohydrazide, an acylhydrazone that joins a 4-hydroxybenzoyl group to a naphthalene ring through a C=N-NH-C(=O) linkage. Molecular formula C18H14N2O2, molecular weight 290.3 g/mol (PubChem CID 5338394, CAS 303760-60-3). The defined compound is the (E) isomer about the C=N double bond. Having no amino acid sequence, it is characterized as a small molecule: mass spectrometry confirms its mass, and HPLC measures purity against a reference standard. An acylhydrazone can hydrolyze back to its two building blocks, 4-hydroxybenzohydrazide and 2-naphthaldehyde, which HPLC would show as separate peaks. It is supplied as a lyophilized powder in a sealed vial.
What the published research covers
First published in 2023 from work in mice, where it was studied in relation to skeletal muscle and energy expenditure, with later studies in mice and cultured cells. No human trial has been published.
SLU-PP-332 is a synthetic small molecule from the laboratory of Thomas Burris and collaborating chemists at Saint Louis University, the source of the SLU in its name. It was designed to activate the estrogen-related receptors ERR alpha, beta and gamma: orphan nuclear receptors that, despite the name, are not activated by estrogen and that regulate genes of mitochondrial function and fatty acid oxidation. Earlier synthetic agonists acted on ERR beta and gamma; the 2023 report described SLU-PP-332 as a pan-agonist with its highest potency at ERR alpha and with pharmacokinetic properties adequate for use in mice (Billon, 2023).
In that first study, the compound increased mitochondrial function and cellular respiration in a skeletal muscle cell line, and in mice it increased oxidative type IIa muscle fibers and exercise endurance, effects for which ERR alpha activation was critical (Billon, 2023). In a Georgetown-led study, 21-month-old mice given the compound for eight weeks showed reversal of age-related albuminuria, podocyte loss, mitochondrial dysfunction and inflammatory cytokines in the kidney (Wang, 2023). In diet-induced obese and ob/ob mice, the St. Louis group reported increased energy expenditure and fatty acid oxidation, less fat mass accumulation and improved insulin sensitivity (Billon, 2024). In a mouse model of pressure-overload heart failure, SLU-PP-332 and a second agonist, SLU-PP-915, improved ejection fraction, reduced fibrosis and increased survival, with ERR gamma as the main mediator (Xu, 2024). In myoblasts cultured from muscle biopsies of physically inactive women, it raised levels of PGC-1alpha, ERR alpha and SIRT1 and promoted myotube formation (Bonanni, 2025). Anti-doping laboratories have since identified 22 of its metabolites formed by human liver fractions (Avliyakulov, 2026).
Every whole-animal result is in mice, most of the work comes from a small number of collaborating groups, and three authors of the founding paper disclosed that they hold stock in a company developing ERR-based therapeutics. No human trial has been published; the human material studied so far is cultured cells and liver fractions. How the compound behaves outside mice, and how selective it is among the three receptors in living tissue, are not established.
Regulatory status
Not approved by the FDA for any use. Supplied for laboratory research only.
Testing and documentation
This is a small molecule, not a peptide: identity is confirmed by mass spectrometry and purity by HPLC against a reference standard. The certificate of analysis for the batch is reachable from the code on the vial.
Questions laboratories ask
- What strength is SLU-PP-332 offered in?
- Vials of 5 mg, as listed on the product page. The amount is on the vial label and on the certificate of analysis for the batch.
- Is SLU-PP-332 a peptide?
- No. It is a synthetic small molecule of about 290 g/mol that acts on nuclear receptors. It appears in this catalog alongside peptides but is tested as a small molecule, against a reference standard.
- Has it been studied in people?
- No human trial has been published. The published work is in mice, in cultured cells, and in human liver fractions used to identify its metabolites.
- How is a batch tested?
- By an independent laboratory: identity by mass spectrometry and purity by HPLC against a reference standard. The QR code on the vial opens the certificate of analysis for that exact batch; no account is needed to read it.
- Who can order, and how does it ship?
- Orders are accepted under the Research Use Agreement, reaffirmed with every order. Orders ship from Montana, the next business day when paid by card, to United States addresses only and not to freight forwarders.
References
- Billon C et al. (2023). Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology. PubMed 36988910
- Wang XX et al. (2023). Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. American Journal of Pathology. PubMed 37717940
- Billon C et al. (2024). A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics. PubMed 37739806
- Xu W et al. (2024). Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation. PubMed 37961903
- Bonanni R et al. (2025). Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. Frontiers in Physiology. PubMed 40692696
- Avliyakulov NK et al. (2026). Analysis and Identification of In Vitro Metabolites of Exercise Mimetic SLU-PP-332 ERRα/β/γ Agonist for Doping-Control Purposes. Drug Testing and Analysis. PubMed 41688415
How it ships
Ordering
Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.
Research use only
This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement